Company news

Share this article:
Johnson & Johnson Nordic AB, a Johnson & Johnson company, announced the acquisition of Amic, a privately held Swedish developer of in vitro diagnostic technologies for use in point-of-care and near-patient settings. The acquisition will provide J&J's Ortho-Clinical Diagnostics with access to a high performance technology platform. As a result of the acquisition, Johnson & Johnson expects to incur an estimated one-time after-tax charge of approximately $40 million during the second quarter of 2008 related to the expensing of in-process research and development. Other terms of the transaction were not disclosed.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.